Use of an Integrated Pan-Cancer Oncology Enrichment Next-Generation Sequencing Assay to Measure Tumour Mutational Burden and Detect Clinically Actionable Variants

被引：0
|
作者：
Valerie Pestinger
Matthew Smith
Toju Sillo
John M. Findlay
Jean-Francois Laes
Gerald Martin
Gary Middleton
Phillipe Taniere
Andrew D. Beggs
机构：
[1] University of Birmingham,Surgical Research Laboratory, Institute of Cancer and Genomic Sciences
[2] Queen Elizabeth Hospital Birmingham,Institute of Immunology and Immunotherapy
[3] Northern Devon Healthcare NHS Trust,undefined
[4] OncoDNA,undefined
[5] PierianDx,undefined
[6] University of Birmingham,undefined
来源：
Molecular Diagnosis & Therapy | 2020年 / 24卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：339 / 349
页数：10
相关论文
共 31 条
  • [21] Noise Reduction Using a Positional Variant-Dependent Error Model for the Detection of Low Frequency Variants in a Pan-Cancer Next-Generation Sequencing Panel
    Laing, C.
    Wahl, J.
    Riccitelli, N.
    Valencia, N.
    Fu, J.
    Pollner, R.
    JOURNAL OF MOLECULAR DIAGNOSTICS, 2020, 22 (11): : S53 - S53
  • [22] A substantial proportion of apparently heterozygous TP53 pathogenic variants detected with a next-generation sequencing hereditary pan-cancer panel are acquired somatically
    Coffee, Bradford
    Cox, Hannah C.
    Bernhisel, Ryan
    Manley, Susan
    Bowles, Karla
    Roa, Benjamin B.
    Mancini-DiNardo, Debora
    HUMAN MUTATION, 2020, 41 (01) : 203 - 211
  • [23] SWI/SNF complex gene variations are associated with a higher tumor mutational burden and a better response to immune checkpoint inhibitor treatment: a pan-cancer analysis of next-generation sequencing data corresponding to 4591 cases
    Yue Li
    Xinhua Yang
    Weijie Zhu
    Yuxia Xu
    Jiangjun Ma
    Caiyun He
    Fang Wang
    Cancer Cell International, 22
  • [24] SWI/SNF complex gene variations are associated with a higher tumor mutational burden and a better response to immune checkpoint inhibitor treatment: a pan-cancer analysis of next-generation sequencing data corresponding to 4591 cases
    Li, Yue
    Yang, Xinhua
    Zhu, Weijie
    Xu, Yuxia
    Ma, Jiangjun
    He, Caiyun
    Wang, Fang
    CANCER CELL INTERNATIONAL, 2022, 22 (01)
  • [25] Panel-based tumor mutational burden (TMB) analysis of matched tumor and plasma specimens using Illumina's TruSight Oncology 500 next-generation sequencing assay
    Hastings, Stephanie B.
    Hariani, Gunjan
    Weigman, Victor J.
    Jiang, Tingting
    Zhao, Chen
    Raja, Rajiv
    Pawlowski, Traci
    Brohawn, Philip
    Hurban, Patrick
    CANCER RESEARCH, 2019, 79 (13)
  • [26] Single-nucleotide variants, tumour mutational burden and microsatellite instability in patients with metastatic colorectal cancer: Next-generation sequencing results of the FIRE-3 trial (vol 137, pg 250, 2020)
    Stahler, Arndt
    Stintzing, Sebastian
    von Einem, Jobst C.
    Westphalen , Christoph B.
    Heinrich, Kathrin
    Kraemer, Nicole
    Michl, Marlies
    Modest, Dominik P.
    von Weikersthal, Ludwig Fischer
    Decker, Thomas
    Kiani, Alexander
    Heintges, Tobias
    Kahl, Christoph
    Kullmann, Frank
    Scheithauer, Werner
    Moehler, Markus
    Kaiser, Florian
    Kirchner, Thomas
    Jung, Andreas
    Heinemann, Volker
    EUROPEAN JOURNAL OF CANCER, 2022, 169 : 223 - 225
  • [27] Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT) A Hybridization Capture-Based Next-Generation Sequencing Clinical Assay for Solid Tumor Molecular Oncology
    Cheng, Donavan T.
    Mitchell, Talia N.
    Zehir, Ahmet
    Shah, Ronak H.
    Benayed, Ryma
    Syed, Aijazuddin
    Chandramohan, Raghu
    Liu, Zhen Yu
    Won, Helen H.
    Scott, Sasinya N.
    Brannon, A. Rose
    O'Reilly, Catherine
    Sadowska, Justyna
    Casanova, Jacklyn
    Yannes, Angela
    Hechtman, Jaclyn F.
    Yao, Jinjuan
    Song, Wei
    Ross, Dara S.
    Oultache, Alifya
    Dogan, Snjezana
    Borsu, Laetitia
    Hameed, Meera
    Nafa, Khedoudja
    Arcila, Maria E.
    Ladanyi, Marc
    Berger, Michael F.
    JOURNAL OF MOLECULAR DIAGNOSTICS, 2015, 17 (03): : 251 - 264
  • [28] Assessment of Blood Tumor Mutational Burden as a Potential Biomarker for Immunotherapy in Patients With Non-Small Cell Lung Cancer With Use of a Next-Generation Sequencing Cancer Gene Panel
    Wang, Zhijie
    Duan, Jianchun
    Cai, Shangli
    Han, Miao
    Dong, Hua
    Zhao, Jun
    Zhu, Bo
    Wang, Shuhang
    Zhuo, Minglei
    Sun, Jianguo
    Wang, Qiming
    Bai, Hua
    Han, Jiefei
    Tian, Yanhua
    Lu, Jing
    Xu, Tongfu
    Zhao, Xiaochen
    Wang, Guoqiang
    Cao, Xinkai
    Li, Fugen
    Wang, Dalei
    Chen, Yuejun
    Bai, Yuezong
    Zhao, Jing
    Zhao, Zhengyi
    Zhang, Yuzi
    Xiong, Lei
    He, Jie
    Gao, Shugeng
    Wang, Jie
    JAMA ONCOLOGY, 2019, 5 (05) : 696 - 702
  • [29] Tumour mutational burden and HLA diversity by TruSight oncology 500 (TSO500) next generation sequencing panel and clinical outcome in non-small cell lung cancer
    Cuppens, K.
    Froyen, G.
    Cruys, B.
    Geerdens, E.
    Zhang, S.
    Zhang, B.
    Decoster, L.
    Thomeer, M.
    Maes, B.
    ANNALS OF ONCOLOGY, 2020, 31 : S713 - S714
  • [30] Next-Generation Sequencing Analysis of Mutations in Circulating Tumor DNA from the Plasma of Patients with Head-Neck Cancer Undergoing Chemo-Radiotherapy Using a Pan-Cancer Cell-Free Assay
    Koukourakis, Michael I.
    Xanthopoulou, Erasmia
    Koukourakis, Ioannis M.
    Fortis, Sotirios P.
    Kesesidis, Nikolaos
    Kakouratos, Christos
    Karakasiliotis, Ioannis
    Baxevanis, Constantin N.
    CURRENT ONCOLOGY, 2023, 30 (10) : 8902 - 8915
1234